Skip to main content

Table 1 Cohort description

From: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options

Patient Details Total (n = 132)
Age at diagnosis: mean years (SD ±) 53.3 (SD ±13.6)
Time to recurrence: mean months (SD ±) 38.7 (SD ±27.7)
Recurrence location
 Loco-regional 58 (44%)
 Distal 74 (56%)
Neoadjuvant Chemo Rx
 Received 58 (44%)
 Did not receive 74 (56%)
Surgery
 Mastectomy 83 (62.8%)
 Wide local excision 49 (37.2%)
Survival: Months
 Overall: mean (SD ±) 60 (38.3)
 Post-recurrence survival: mean (SD ±) 20.7 (21.1)
Original subtype
 Luminal A 67 (50.7%)
 Luminal B 10 (7.5%)
 HER2 15 (11.3%)
 Triple negative 40 (30.5%)
Recurrence subtype
 Luminal A 54 (40.9%)
 Luminal B 9 (6.9%)
 HER2 16 (12.1%)
 Triple negative 53 (40.1%)